FINWIRES · TerminalLIVE
FINWIRES

$MRK

39 stories mentioning MRK

Every FINWIRES story that references MRK, newest first.

Sectors

Sector Update: Healthcare Stocks Softer Late Afternoon

Healthcare stocks edged lower late Friday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each decreasing 0.2%.The iShares Biotechnology ETF (IBB) increased 0.2%.In corporate news, Merck's (MRK) Belzutifan in combination with pembrolizumab has been approved for the adjuvant treatment of adults with renal cell carcinoma, the US Food and Drug Administration said Friday. Merck shares were down 1%.AstraZeneca (AZN) said Friday the US Food and Drug Administration approved Truqap in combination with abiraterone and prednisone for adults with PTEN-deficient metastatic androgen pathway modulation-naive or sensitive prostate cancer. AstraZeneca shares were declining 1.6%.Jazz Pharmaceuticals (JAZZ) shares fell 1.2% after it said a phase 3 trial of Zepzelca in second-line metastatic small cell lung cancer failed to meet its primary endpoint.Avalo Therapeutics' (AVTX) lead drug abdakibart is now a cleaner immunology story following positive phase 2 trial data to treat skin disease hidradenitis suppurativa, BofA Securities said. BofA started coverage of the stock with a buy rating and a price target of $35. Avalo shares jumped past 7%.

$AVTX$AZN$JAZZ$MRK
Sectors

Sector Update: Healthcare

Healthcare stocks edged lower late Friday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each decreasing 0.2%.The iShares Biotechnology ETF (IBB) increased 0.1%.In corporate news, Merck's (MRK) Belzutifan in combination with pembrolizumab has been approved for the adjuvant treatment of adults with renal cell carcinoma, the US Food and Drug Administration said Friday. Merck shares were down 0.8%.

$MRK
Wire

Merck's Belzutifan Combination Approved by FDA for Adjuvant Treatment of Renal Cell Carcinoma

Merck's (MRK) Belzutifan in combination with pembrolizumab has been approved for the adjuvant treatment of adults with renal cell carcinoma, the US Food and Drug Administration said Friday.It is also approved for the combination with pembrolizumab and berahyaluronidase alfa-pmph, the FDA said.The treatment is for patients with a clear cell component at intermediate to high risk of recurrence following nephrectomy, or after nephrectomy and resection of metastatic lesions, it said.Price: $119.95, Change: $-0.81, Percent Change: -0.67%

$MRK
Sectors

Sector Update: Healthcare Stocks Climb Late Afternoon

Healthcare stocks were higher late Thursday afternoon, with the NYSE Healthcare Index climbing 3.2% and the State Street Health Care Select Sector SPDR ETF (XLV) rising 3%.The iShares Biotechnology ETF (IBB) added 2.6%.In corporate news, Eli Lilly (LLY) shares gained 4.3% after Ascidian Therapeutics said Lilly will receive exclusive, target-specific rights to Ascidian's RNA exon editing technology for undisclosed kidney disease targets in exchange for up to $1.9 billion under a research partnership and licensing deal.Merck (MRK) shares climbed 5% after it said Thursday it will pay over $50 million to settle more than 200 lawsuits that blame the drugmaker's Gardasil cancer vaccine for causing autoimmune ailments in young women, Bloomberg reported.The US Supreme Court on Thursday ruled that Amarin (AMRN) failed to prove that a generic-drug manufacturer actively induced other companies to infringe upon two of its Vascepa patents after the generic maker received approval for a so-called "skinny-label" version of the drug. Amarin shares fell 4.4%.BofA Securities upgraded UnitedHealth (UNH) to buy from neutral as medical cost trends improve and "supportive" near-term data points form a favorable Q2. UnitedHealth shares rose 5.4%.

$AMRN$LLY$MRK$UNH
Sectors

Sector Update: Healthcare Stocks Gain Thursday Afternoon

Healthcare stocks were higher Thursday afternoon, with the NYSE Healthcare Index climbing 3.2% and the State Street Health Care Select Sector SPDR ETF (XLV) rising 2.8%.The iShares Biotechnology ETF (IBB) added 2.2%.In corporate news, Eli Lilly (LLY) shares climbed 5% after Ascidian Therapeutics said Lilly will receive exclusive, target-specific rights to Ascidian's RNA exon editing technology for undisclosed kidney disease targets in exchange for up to $1.9 billion under a research partnership and licensing deal.Merck (MRK) shares rose 3.9% after it said Thursday it will pay over $50 million to settle more than 200 lawsuits that blame the drugmaker's Gardasil cancer vaccine for causing autoimmune ailments in young women, Bloomberg reported.BofA Securities upgraded UnitedHealth (UNH) to buy from neutral as medical cost trends improvement and "supportive" near-term data points form a favorable Q2. UnitedHealth shares gained 5.2%.

$LLY$MRK$UNH
Wire

Market Chatter: Merck to Pay Over $50 Million to Settle More Than 200 Gardasil Cases

Merck (MRK) said Thursday it will pay over $50 million to settle more than 200 lawsuits that blame the drugmaker's Gardasil cancer vaccine for causing autoimmune ailments in young women, Bloomberg reported, citing an emailed statement from the company.Gardasil prevents human papillomavirus infections. The lawsuits allege it can cause autoimmune conditions affecting the heart and reproductive systems in young women, according to the report.Merck didn't immediately reply to a request for comment from.Price: $119.28, Change: $+4.58, Percent Change: +3.99%

$MRK
Wire

Merck to Pay Over $50 Million to Settle More Than 200 Gardasil Cases, Bloomberg Reports

Merck to Pay Over $50 Million to Settle More Than 200 Gardasil Cases, Bloomberg Reports

$MRK
Wire

Merck Keeps Quarterly Dividend at $0.85 a Share, Payable July 8 to Holders of Record June 15

Merck Keeps Quarterly Dividend at $0.85 a Share, Payable July 8 to Holders of Record June 15

$MRK
Asia Markets

US Equity Indexes Rise, Crude Oil Off Session Highs as Iran Peace Talks Press Ahead

US equity indexes rose as pressure on government bond yields eased and crude oil retreated from intraday highs amid intense diplomacy to reach a deal with Iran.The Nasdaq Composite rose 0.2% to 26,343.97, with the S&P 500 up 0.4% to 7,473.47 and the Dow Jones Industrial Average higher by 0.6% to 50,579.70. The Dow hit an all-time high of 50,830.24, according to data compiled by CNBC.Iran said peace negotiations with the US face "deep and significant" differences, and it's difficult to say if a deal can be reached over the next "weeks or months," Al Jazeera reported Friday.A Qatari negotiating team arrived in Tehran on Friday in coordination with the US to help secure a deal to end the war, Reuters reported, citing a source with knowledge of the matter. Pakistan's army chief Asim Munir is headed to Tehran to help mediate a settlement, Al Jazeera reported Friday.While there are "good signs" that an agreement to end the conflict is in sight, any deal would be "unfeasible" if Iran pursues measures to permanently control the Strait of Hormuz, US Secretary of State Marco Rubio said on Thursday, according to CNBC. The US plans to seize Tehran's stockpile of enriched uranium as part of peace negotiations, President Donald Trump reportedly said Thursday.West Texas Intermediate crude oil futures rose 0.1% to $96.44, and Brent crude futures climbed 0.9% to $103.54. The WTI and Brent futures traded more than 3% higher earlier in the day.US Treasury yields were mixed, with the 10-year down 2.6 basis points to 4.56% and the 30-year down 4.7 basis points to 5.06%. The two-year yield, however, rose 3.6 basis points to 4.12%.In economic news, the Conference Board's measure of leading indicators rose by 0.1% in April following a 0.6% decrease in March.The University of Michigan consumer sentiment index was revised down to 44.8 for May from a preliminary reading of 48.2, compared with expectations for no revision in a Bloomberg-compiled survey and a drop from the final 49.8 in April.Respondents in the Michigan survey expected a 4.8% inflation rate over the next year and 3.9% annual inflation over the next five years, up from 4.7% and 3.5%, respectively, in April.In company news, Dell Technologies (DELL) shares jumped 17%, the top gainer on the S&P 500, after Wells Fargo raised its price target to $270 from $180.Take-Two Interactive Software (TTWO) reported a narrower fiscal Q4 net loss as revenue increased. MoffettNathanson adjusted its price target on the company's shares to $196 from $206 while maintaining its neutral rating. Take-Two shares slumped 4.4%, the second-steepest decline on the Nasdaq.Merck (MRK) said Friday the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended the approval of Keytruda, in combination with Padcev, to treat a type of bladder cancer. Shares of Merck jumped 5.6%, the Dow's top performer.

Dow JonesNasdaq CompositeS&P 500$DELL$MRK$TTWO
Sectors

Sector Update: Healthcare Stocks Gain Late Afternoon

Healthcare stocks rose late Friday afternoon, with the NYSE Healthcare Index advancing 1.1% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1.3%.The iShares Biotechnology ETF (IBB) was fractionally lower.In corporate news, Eli Lilly (LLY) shares rose 2.5% after it said Friday that a new analysis from two phase 3 trials showed that its GLP-1 pill Foundayo at all doses tested was linked to "clinically significant" weight loss in adults 65 years old and older with obesity or overweight.Novo Nordisk's (NVO) Ozempic and Eli Lilly's Mounjaro are being linked to better cancer outcomes in four new studies, The Wall Street Journal reported. The weight-loss and diabetes drugs suggest they could reduce tumor progression, lower overall chance of death, and avert the risk of developing breast cancer, the report said. Novo shares added 1%.Merck (MRK) said Friday the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended the approval of Keytruda, in combination with Padcev, to treat a type of bladder cancer. Merck shares jumped 5.6%.Gilead Sciences (GILD) shares gained 2.9%. The company has received approval from the US Food and Drug Administration for Hepcludex to treat chronic hepatitis delta virus infection in adults without advanced liver scarring, or with compensated cirrhosis, the FDA said Friday.

$GILD$LLY$MRK$NVO
Research

Research Alert: CFRA Raises Opinion On Shares Of Merck & Co., Inc. To Strong Buy From Buy

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lift our target to $149 from $135, 14.8x our 2027 EPS view, slightly above MRK's 10-yr historical forward P/E average. We lower our 2026 EPS to $2.80 from $5.05 to account for acquisition-related charges (Terns deal). The EMA's backing of Keytruda-Padcev combo to treat bladder cancer can widen Keytruda's addressable market considerably, in our view. The EMA issued a positive opinion for approval today of MRK's key drug Keytruda in combo with Padcev, as a perioperative treatment (before and after surgery) for adults with resectable muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy. The Phase 3 KEYNOTE-905 trial demonstrated that the combo reduced recurrence, progression, or death risk by 60% and death risk versus surgery alone by 50%. If approved (decision expected in Q3), this would become the first and only PD-1 inhibitor plus antibody-drug conjugate regimen for this patient population in the EU, addressing a significant unmet need for a considerable patient population.

$MRK
Sectors

Sector Update: Healthcare Stocks Gain Friday Afternoon

Healthcare stocks rose Friday afternoon, with the NYSE Healthcare Index advancing 0.8% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1.2%.The iShares Biotechnology ETF (IBB) increased 0.2%.In corporate news, Merck (MRK) said Friday the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended the approval of Keytruda, in combination with Padcev, to treat a type of bladder cancer. Merck shares jumped 5%.Eli Lilly (LLY) shares rose 2.2% after it said Friday that a new analysis from two phase 3 trials showed that its GLP-1 pill Foundayo at all doses tested was linked to "clinically significant" weight loss in adults 65 years old and older with obesity or overweight.Novo Nordisk's (NVO) Ozempic and Eli Lilly's Mounjaro are being linked to better cancer outcomes in four new studies, The Wall Street Journal reported. The weight-loss and diabetes drugs suggest they could reduce tumor progression, lower overall chance of death, and avert the risk of developing breast cancer, the report said. Novo shares added 1%.

$LLY$MRK$NVO
Sectors

Sector Update: Healthcare

Healthcare stocks rose Friday afternoon, with the NYSE Healthcare Index advancing 1% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1.1%.The iShares Biotechnology ETF (IBB) increased 0.1%.In corporate news, Merck (MRK) said Friday the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended the approval of Keytruda, in combination with Padcev, to treat a type of bladder cancer. Merck shares jumped 5.2%.

$MRK
Asia Markets

US Equity Indexes Rise as Momentum Builds to Secure Iran Peace Agreement

US equity indexes rose as pressure on government bond yields eased and crude oil retreated from intraday highs amid progress in Iran peace talks.The Nasdaq Composite rose 0.5% to 26,423.4, with the S&P 500 up 0.6% to 7,488.2 and the Dow Jones Industrial Average higher by 0.8% to 50,709.3 in Friday's midday trading. The Dow hit an all-time high of 50,746.25, according to data compiled by CNBC.A Qatari negotiating team arrived in Tehran on Friday in coordination with the US to help secure a deal to end the war, Reuters reported, citing a source with knowledge of the matter. Pakistan's army chief Asim Munir is headed to Tehran to help mediate a settlement, Al Jazeera reported Friday.While there are "good signs" that an agreement to end the conflict is in sight, any deal would be "unfeasible" if Iran pursues measures to permanently control the Strait of Hormuz, US Secretary of State Marco Rubio said on Thursday, according to CNBC. The US plans to seize Tehran's stockpile of enriched uranium as part of peace negotiations, President Donald Trump reportedly said Thursday.West Texas Intermediate crude oil futures rose 0.8% to $97.19, and Brent crude futures climbed 1.1% to $103.65. The WTI and Brent futures traded more than 3% higher earlier in the day.US Treasury yields were mixed, with the 10-year down 1.6 basis points to 4.57% and the 30-year down 3.4 basis points to 5.08%. The two-year yield, however, rose 3.8 basis points to 4.13%.In economic news, the Conference Board's measure of leading indicators rose by 0.1% in April following a 0.6% decrease in March."Strong investment in AI infrastructure, data centers, and energy production likely will have a positive impact on growth and sustain business spending but may only partially offset weakness on the consumer side," said Justyna Zabinska-La Monica, Senior Manager for Business Cycle Indicators.The University of Michigan consumer sentiment index was revised down to 44.8 for May from 48.2 preliminary, compared with expectations for no revision in a Bloomberg-compiled survey and a drop from the final 49.8 in April. Respondents expected a 4.8% inflation rate over the next year and 3.9% annual inflation over the next five years, up from 4.7% and 3.5%, respectively, in April."Consumer sentiment fell for the third straight month as supply disruptions in the Strait of Hormuz continue to boost gasoline prices," Michigan said.In company news, Dell Technologies (DELL) shares jumped 17%, the top gainer on the S&P 500, after Wells Fargo raised its price target to $270 from $180.Take-Two Interactive Software (TTWO) reported a narrower fiscal Q4 net loss as revenue increased. MoffettNathanson adjusted its price target on the company's shares to $196 from $206 while maintaining its neutral rating. Take-Two shares slumped 4.3%, the steepest decline on the Nasdaq.Merck (MRK) said Friday the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended the approval of Keytruda, in combination with Padcev, to treat a type of bladder cancer. Shares of Merck jumped 5.4%, the Dow's top performer.

Dow JonesNasdaq CompositeS&P 500$DELL$MRK$TTWO
Wire

Merck's Keytruda, Padcev Combination to Treat Bladder Cancer Receives Positive EU Recommendation; Shares Up Pre-Bell

Merck (MRK) said Friday the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended the approval of Keytruda, in combination with Padcev, to treat a type of bladder cancer.The pharmaceutical company said the treatment is preoperative, which then continues after radical cystectomy as supportive treatment for adults with resectable muscle-invasive bladder cancer. The treatment is indicated for patients who are ineligible for cisplatin-containing chemotherapy.Shares of Merck were up more than 3% pre-bell.Price: $119.50, Change: $+3.62, Percent Change: +3.12%

$MRK
Sectors

Sector Update: Healthcare Stocks Mixed in Afternoon Trading

Healthcare stocks were mixed Monday afternoon with the NYSE Healthcare Index rising 0.2% and the State Street Healthcare Select Sector SPDR ETF (XLV) little changed, paring earlier losses.The iShares Biotechnology ETF (IBB) increased 0.3%.In corporate news, Moderna (MRNA) has been working on early-stage vaccines targeting hantaviruses, Bloomberg reported Friday, citing a company statement. The research began before recent infections were reported aboard the Dutch-flagged Hondius, the report said. Moderna shares fell 2.2%.Sonida Senior Living (SNDA) shares fell 3.6% after the company reported Q1 loss of $2.39 per diluted share, widening from the loss of $0.77 a year earlier. Three analysts polled by FactSet expected a loss of $1.53.Erasca (ERAS) entered a clinical trial collaboration and supply agreement with Merck (MRK) to study its investigational drug ERAS-0015 in combination with Keytruda in patients with RAS-mutant solid tumors. Erasca shares rose 3.3%, and Merck added 1.2%.

$ERAS$MRK$MRNA$SNDA
Sectors

Sector Update: Health Care Stocks Higher Late Afternoon

Health care stocks edged higher late Tuesday afternoon, with the NYSE Health Care Index and the State Street Health Care Select Sector SPDR ETF (XLV) each increasing about 0.4%.The iShares Biotechnology ETF (IBB) was up 0.1%.In corporate news, Edgewise Therapeutics (EWTX) shares jumped 22% after Wedbush lifted the company's price target to $46 from $32, while keeping its outperform rating.Pfizer's (PFE) Q1 results surpassed analyst estimates as robust demand across its key brands offset weakening sales of its COVID-19 products. Its shares rose 0.9%.Merck (MRK) shares added 0.6%. The company said Tuesday it has completed the acquisition of Terns Pharmaceuticals after a cash tender offer at $53 per share.Scilex (SCLX) shares were down 3% after it said Tuesday its subsidiary ACEA Therapeutics agreed to transfer 100% of the equity interests of ACEA Pharma to Phoenix Asia (PHOE) in a $1 billion all-stock deal.

$EWTX$MRK$PFE$SCLX
Sectors

Sector Update: Health Care Stocks Advance Tuesday Afternoon

Health care stocks rose Tuesday afternoon, with the NYSE Health Care Index and the State Street Health Care Select Sector SPDR ETF (XLV) increasing 0.3% each.The iShares Biotechnology ETF (IBB) was shedding 0.4%.In corporate news, Pfizer's (PFE) Q1 results surpassed analysts' estimates as robust demand across its key brands offset weakening sales of its COVID-19 products. Its shares declined 0.7%.Merck (MRK) shares added 0.4% after the company said Tuesday it has completed the acquisition of Terns Pharmaceuticals after a cash tender offer at $53 per share. Terns' stock will no longer be listed on Nasdaq, it said.BioNTech (BNTX) shares dropped 3.5% after the company reported a wider adjusted loss and lower revenue in Q1.

$BNTX$MRK$PFE
Wire

Merck Completes Terns Pharmaceuticals Acquisition

Merck (MRK) said Tuesday it has completed the acquisition of Terns Pharmaceuticals after a cash tender offer at $53 per share.Terns' stock will no longer be listed on Nasdaq, it said.The deal will result in a charge to research and development expense of about $2.35 per share, included in Q2 and full year 2026 GAAP and non-GAAP results, Merck said.GAAP and non-GAAP EPS are also expected to take a hit of about $0.12 a share in 2026 on costs associated with advancing TERN-701 and costs of financing, it added.Price: $113.21, Change: $+0.10, Percent Change: +0.09%

$MRK$TERN
Wire

Goldman Sachs Adjusts Merck Price Target to $137 From $133

Merck & Co (MRK) has an average rating of overweight and mean price target of $132.13, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $112.64, Change: $+3.46, Percent Change: +3.17%

$MRK

Showing 1-20 of 39